Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Statin treatment linked to reduced severity of acute pancreatitis

04 Jan 2018

Statins appear to reduce the severity of acute pancreatitis (AP), as demonstrated by a decrease in overall incidence of multisystem organ failure (MSOF), according to a study.

Researchers examined the medical records of adult patients with AP admitted in the Cleveland Clinic Health System between 2007 and 2014. They performed a propensity-matched analysis to assess the effect of statin exposure on the severity of pancreatitis and incidence of organ failure. The propensity model included factors that influence statin use to minimize selection bias.

A total of 110 AP patients on statin at admission were matched with 210 AP patients who were not exposed to the drug. The two patient groups were evenly matched in terms of known baseline factors that may influence statin use and severity of pancreatitis.

Outcomes of interest were pancreatitis severity (Revised Atlanta Classification), incidence of MSOF, new MSOF, acute necrosis, and death. Additional surrogate markers of severity, such as hospital length of stay, Bedside Index of Severity of Acute Pancreatitis (BISAP), and presence of systemic inflammatory response syndrome, were also assessed.

Results revealed that statin use was associated with a lower likelihood of developing MOSF, severe AP, and necrosis. While there were fewer cases of in-hospital death in the statin group than in the unexposed group, the difference was not statistically significant (2 vs 4 percent; p=0.38).

In a previous animal study, statin administration resulted in lower severity of AP, reduced serum levels of interleukin-10, and diminished myeloperoxidase activity. Statins also demonstrated antioxidant effects and helped prevent cell damage. Specifically, pravastatin significantly attenuated the progression of pancreatic inflammation, fibrosis, and exocrine dysfunction, possibly through the drug’s antioxidative properties and overproduction of interleukin-10. On the other hand, lovastatin was associated with the inhibition of pancreatic stellate cell activation through the interruption of RAS signalling. [Am J Gastroenterol 2017;112:1765–1767]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.